{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:05:28Z","timestamp":1794265528268,"version":"4.9.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A high proportion of patients with coronavirus disease 2019 (COVID-19) experience post-acute COVID-19, including neuropsychiatric symptoms. Objective signs of central nervous system (CNS) damage can be investigated using CNS biomarkers such as glial fibrillary acidic protein (GFAp), neurofilament light chain (NfL) and total tau (t-tau). We have examined whether CNS biomarkers can predict fatigue and cognitive impairment 3\u20136\u00a0months after discharge from the intensive care unit (ICU) in critically ill COVID-19 patients. Fifty-seven COVID-19 patients admitted to the ICU were included with analysis of CNS biomarkers in blood at the ICU and at follow up. Cognitive dysfunction and fatigue were assessed with the Montreal Cognitive Assessment (MoCA) and the Multidimensional Fatigue inventory (MFI-20). Elevated GFAp at follow-up 3\u20136\u00a0months after ICU discharge was associated to the development of mild cognitive dysfunction (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01), especially in women (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.005). Patients who experienced different dimensions of fatigue at follow-up had significantly lower GFAp in both the ICU and at follow-up, specifically in general fatigue (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009), physical fatigue (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004), mental fatigue (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001), and reduced motivation (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001). Women showed a more pronounced decrease in GFAp compared to men, except for in mental fatigue where men showed a more pronounced GFAp decrease compared to women. NfL concentration at follow-up was lower in patients who experienced reduced motivation (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004). Our findings suggest that GFAp and NfL are associated with neuropsychiatric outcome after critical COVID-19.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:italic>Trial registration<\/jats:italic>\n                    The study was registered \u00e0 priori (clinicaltrials.gov: NCT04316884 registered on 2020-03-13 and NCT04474249 registered on 2020-06-29).\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-39698-y","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T06:01:51Z","timestamp":1691820111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19"],"prefix":"10.1038","volume":"13","author":[{"given":"Lovisa","family":"Bark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ing-Marie","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Simr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Lipcsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Frithiof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Rostami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hultstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"issue":"6","key":"39698_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamaneurol.2020.1127","volume":"77","author":"L Mao","year":"2020","unstructured":"Mao, L. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 77(6), 683\u2013690 (2020).","journal-title":"JAMA Neurol."},{"issue":"7","key":"39698_CR2","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.clinph.2021.03.016","volume":"132","author":"R Frithiof","year":"2021","unstructured":"Frithiof, R. et al. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. Clin. Neurophysiol. 132(7), 1733\u20131740 (2021).","journal-title":"Clin. Neurophysiol."},{"issue":"22","key":"39698_CR3","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2020.22717","volume":"324","author":"SD Datta","year":"2020","unstructured":"Datta, S. D., Talwar, A. & Lee, J. T. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: Illness beyond acute infection and public health implications. JAMA 324(22), 2251\u20132252 (2020).","journal-title":"JAMA"},{"issue":"6","key":"39698_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2020.12603","volume":"324","author":"A Carfi","year":"2020","unstructured":"Carfi, A., Bernabei, R. & Landi, F. Gemelli against C-P-ACSG: Persistent symptoms in patients after acute COVID-19. JAMA 324(6), 603\u2013605 (2020).","journal-title":"JAMA"},{"issue":"4","key":"39698_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27(4), 601\u2013615 (2021).","journal-title":"Nat. Med."},{"issue":"11","key":"39698_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240784","volume":"15","author":"L Townsend","year":"2020","unstructured":"Townsend, L. et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS ONE 15(11), e0240784 (2020).","journal-title":"PLoS ONE"},{"issue":"10270","key":"39698_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S0140-6736(20)32656-8","volume":"397","author":"C Huang","year":"2021","unstructured":"Huang, C. et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet 397(10270), 220\u2013232 (2021).","journal-title":"Lancet"},{"issue":"5","key":"39698_CR8","doi-asserted-by":"publisher","first-page":"e1089","DOI":"10.1093\/cid\/ciaa1750","volume":"73","author":"B van den Borst","year":"2021","unstructured":"van den Borst, B. et al. Comprehensive health assessment 3 months after recovery from acute coronavirus disease 2019 (COVID-19). Clin. Infect. Dis. 73(5), e1089\u2013e1098 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"39698_CR9","doi-asserted-by":"crossref","unstructured":"Writing Committee for the CSG, Morin, L., Savale, L., Pham, T., Colle, R., Figueiredo, S., Harrois, A., Gasnier, M., Lecoq, A. L. & Meyrignac, O. et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021, 325(15):1525\u20131534.","DOI":"10.1001\/jama.2021.3331"},{"key":"39698_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117486","volume":"426","author":"JA Frontera","year":"2021","unstructured":"Frontera, J. A. et al. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. J. Neurol. Sci. 426, 117486 (2021).","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"39698_CR11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/CCM.0b013e318232da75","volume":"40","author":"DM Needham","year":"2012","unstructured":"Needham, D. M. et al. Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders\u2019 conference. Crit. Care Med. 40(2), 502\u2013509 (2012).","journal-title":"Crit. Care Med."},{"issue":"9","key":"39698_CR12","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/CCM.0000000000003218","volume":"46","author":"A Marra","year":"2018","unstructured":"Marra, A. et al. Co-occurrence of post-intensive care syndrome problems among 406 survivors of critical illness. Crit. Care Med. 46(9), 1393\u20131401 (2018).","journal-title":"Crit. Care Med."},{"issue":"4","key":"39698_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/glia.20207","volume":"50","author":"M Pekny","year":"2005","unstructured":"Pekny, M. & Nilsson, M. Astrocyte activation and reactive gliosis. Glia 50(4), 427\u2013434 (2005).","journal-title":"Glia"},{"issue":"10","key":"39698_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14(10), 577\u2013589 (2018).","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"39698_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang, Y. & Mandelkow, E. Tau in physiology and pathology. Nat. Rev. Neurosci. 17(1), 5\u201321 (2016).","journal-title":"Nat. Rev. Neurosci."},{"issue":"602","key":"39698_CR16","doi-asserted-by":"publisher","first-page":"eabi7643","DOI":"10.1126\/scitranslmed.abi7643","volume":"13","author":"M Prudencio","year":"2021","unstructured":"Prudencio, M. et al. Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. Sci. Transl. Med. 13(602), eabi7643 (2021).","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"39698_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ana.26004","volume":"89","author":"R Sutter","year":"2021","unstructured":"Sutter, R. et al. Serum neurofilament light chain levels in the intensive care unit: Comparison between severely ill patients with and without coronavirus disease 2019. Ann. Neurol. 89(3), 610\u2013616 (2021).","journal-title":"Ann. Neurol."},{"issue":"12","key":"39698_CR18","doi-asserted-by":"publisher","first-page":"e1754","DOI":"10.1212\/WNL.0000000000010111","volume":"95","author":"N Kanberg","year":"2020","unstructured":"Kanberg, N. et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology 95(12), e1754\u2013e1759 (2020).","journal-title":"Neurology"},{"key":"39698_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103512","volume":"70","author":"N Kanberg","year":"2021","unstructured":"Kanberg, N. et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine 70, 103512 (2021).","journal-title":"EBioMedicine"},{"issue":"10","key":"39698_CR20","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s00134-005-2762-6","volume":"31","author":"PG Metnitz","year":"2005","unstructured":"Metnitz, P. G. et al. SAPS 3\u2013From evaluation of the patient to evaluation of the intensive care unit Part 1: Objectives, methods and cohort description. Intensive Care Med. 31(10), 1336\u20131344 (2005).","journal-title":"Intensive Care Med."},{"issue":"3","key":"39698_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0022-3999(94)00125-O","volume":"39","author":"EM Smets","year":"1995","unstructured":"Smets, E. M., Garssen, B., Bonke, B. & De Haes, J. C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 39(3), 315\u2013325 (1995).","journal-title":"J. Psychosom. Res."},{"issue":"4","key":"39698_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine, Z. S. et al. The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc. 53(4), 695\u2013699 (2005).","journal-title":"J. Am. Geriatr. Soc."},{"issue":"5","key":"39698_CR23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/0022-3468(90)90563-O","volume":"25","author":"H Kato","year":"1990","unstructured":"Kato, H. et al. Immunocytochemical characterization of supporting cells in the enteric nervous system in Hirschsprung\u2019s disease. J. Pediatr. Surg. 25(5), 514\u2013519 (1990).","journal-title":"J. Pediatr. Surg."},{"issue":"1\u20132","key":"39698_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/0006-8993(92)90583-U","volume":"570","author":"D Bianchini","year":"1992","unstructured":"Bianchini, D. et al. GFAP expression of human Schwann cells in tissue culture. Brain Res. 570(1\u20132), 209\u2013217 (1992).","journal-title":"Brain Res."},{"issue":"5","key":"39698_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/jnen\/60.5.449","volume":"60","author":"JA Hainfellner","year":"2001","unstructured":"Hainfellner, J. A. et al. Fibroblasts can express glial fibrillary acidic protein (GFAP) in vivo. J. Neuropathol. Exp. Neurol. 60(5), 449\u2013461 (2001).","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"3","key":"39698_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.pneurobio.2011.01.005","volume":"93","author":"J Middeldorp","year":"2011","unstructured":"Middeldorp, J. & Hol, E. M. GFAP in health and disease. Prog. Neurobiol. 93(3), 421\u2013443 (2011).","journal-title":"Prog. Neurobiol."},{"issue":"9\u201310","key":"39698_CR27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1023\/A:1007677003387","volume":"25","author":"LF Eng","year":"2000","unstructured":"Eng, L. F., Ghirnikar, R. S. & Lee, Y. L. Glial fibrillary acidic protein: GFAP-thirty-one years (1969\u20132000). Neurochem. Res. 25(9\u201310), 1439\u20131451 (2000).","journal-title":"Neurochem. Res."},{"issue":"3","key":"39698_CR28","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0306-4522(98)00334-0","volume":"89","author":"TE Morgan","year":"1999","unstructured":"Morgan, T. E. et al. The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience 89(3), 687\u2013699 (1999).","journal-title":"Neuroscience"},{"issue":"5","key":"39698_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0197-4580(93)90100-P","volume":"14","author":"NR Nichols","year":"1993","unstructured":"Nichols, N. R., Day, J. R., Laping, N. J., Johnson, S. A. & Finch, C. E. GFAP mRNA increases with age in rat and human brain. Neurobiol. Aging 14(5), 421\u2013429 (1993).","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"39698_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl, P. et al. Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J. Alzheimers Dis. 67(2), 481\u2013488 (2019).","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"39698_CR31","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/brainsci12050556","volume":"12","author":"T Rudroff","year":"2022","unstructured":"Rudroff, T., Workman, C. D. & Bryant, A. D. Potential factors that contribute to post-COVID-19 fatigue in women. Brain Sci. 12(5), 556 (2022).","journal-title":"Brain Sci."},{"issue":"10","key":"39698_CR32","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1111\/ene.14703","volume":"28","author":"J Virhammar","year":"2021","unstructured":"Virhammar, J. et al. Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity. Eur. J. Neurol. 28(10), 3324\u20133331 (2021).","journal-title":"Eur. J. Neurol."},{"key":"39698_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40560-018-0295-7","volume":"6","author":"GB Wintermann","year":"2018","unstructured":"Wintermann, G. B. et al. Self-reported fatigue following intensive care of chronically critically ill patients: A prospective cohort study. J. Intensive Care 6, 27 (2018).","journal-title":"J. Intensive Care"},{"issue":"10","key":"39698_CR34","first-page":"CD010775","volume":"2015","author":"DH Davis","year":"2015","unstructured":"Davis, D. H. et al. Montreal cognitive assessment for the diagnosis of Alzheimer\u2019s disease and other dementias. Cochrane Database Syst. Rev. 2015(10), CD010775 (2015).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"39698_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/jamaneurol.2018.3223","volume":"76","author":"M Moseby-Knappe","year":"2019","unstructured":"Moseby-Knappe, M. et al. Serum neurofilament light chain for prognosis of outcome after cardiac arrest. JAMA Neurol. 76(1), 64\u201371 (2019).","journal-title":"JAMA Neurol."},{"issue":"14","key":"39698_CR36","doi-asserted-by":"publisher","first-page":"e1338","DOI":"10.1212\/WNL.0000000000006282","volume":"91","author":"S Tiedt","year":"2018","unstructured":"Tiedt, S. et al. Serum neurofilament light: A biomarker of neuroaxonal injury after ischemic stroke. Neurology 91(14), e1338\u2013e1347 (2018).","journal-title":"Neurology"},{"issue":"569","key":"39698_CR37","doi-asserted-by":"publisher","first-page":"eaay1913","DOI":"10.1126\/scitranslmed.aay1913","volume":"12","author":"TF Gendron","year":"2020","unstructured":"Gendron, T. F. et al. Plasma neurofilament light predicts mortality in patients with stroke. Sci. Transl. Med. 12(569), eaay1913 (2020).","journal-title":"Sci. Transl. Med."},{"key":"39698_CR38","doi-asserted-by":"publisher","first-page":"36791","DOI":"10.1038\/srep36791","volume":"6","author":"P Shahim","year":"2016","unstructured":"Shahim, P. et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci. Rep. 6, 36791 (2016).","journal-title":"Sci. Rep."},{"issue":"5","key":"39698_CR39","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/ana.25889","volume":"88","author":"TG Fong","year":"2020","unstructured":"Fong, T. G. et al. Association of plasma neurofilament light with postoperative delirium. Ann. Neurol. 88(5), 984\u2013994 (2020).","journal-title":"Ann. Neurol."},{"issue":"6","key":"39698_CR40","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1001\/jamaneurol.2014.367","volume":"71","author":"P Shahim","year":"2014","unstructured":"Shahim, P. et al. Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol. 71(6), 684\u2013692 (2014).","journal-title":"JAMA Neurol."},{"issue":"20","key":"39698_CR41","doi-asserted-by":"publisher","first-page":"e1780","DOI":"10.1212\/WNL.0000000000005518","volume":"90","author":"P Shahim","year":"2018","unstructured":"Shahim, P., Tegner, Y., Marklund, N., Blennow, K. & Zetterberg, H. Neurofilament light and tau as blood biomarkers for sports-related concussion. Neurology 90(20), e1780\u2013e1788 (2018).","journal-title":"Neurology"},{"key":"39698_CR42","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1146\/annurev-med-050913-015722","volume":"67","author":"TD Girard","year":"2016","unstructured":"Girard, T. D., Dittus, R. S. & Ely, E. W. Critical illness brain injury. Annu. Rev. Med. 67, 497\u2013513 (2016).","journal-title":"Annu. Rev. Med."},{"issue":"12","key":"39698_CR43","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1164\/rccm.201111-2025OC","volume":"185","author":"ME Mikkelsen","year":"2012","unstructured":"Mikkelsen, M. E. et al. The adult respiratory distress syndrome cognitive outcomes study: Long-term neuropsychological function in survivors of acute lung injury. Am. J. Respir. Crit. Care Med. 185(12), 1307\u20131315 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"39698_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1164\/ajrccm.160.1.9708059","volume":"160","author":"RO Hopkins","year":"1999","unstructured":"Hopkins, R. O. et al. Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 160(1), 50\u201356 (1999).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"39698_CR45","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/CCM.0000000000001531","volume":"44","author":"MA Harvey","year":"2016","unstructured":"Harvey, M. A. & Davidson, J. E. Postintensive care syndrome: Right care, right now\u2026and later. Crit. Care Med. 44(2), 381\u2013385 (2016).","journal-title":"Crit. Care Med."},{"issue":"5","key":"39698_CR46","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00134-016-4321-8","volume":"42","author":"MS Herridge","year":"2016","unstructured":"Herridge, M. S. et al. Recovery and outcomes after the acute respiratory distress syndrome (ARDS) in patients and their family caregivers. Intensive Care Med. 42(5), 725\u2013738 (2016).","journal-title":"Intensive Care Med."},{"issue":"9 Suppl 1","key":"39698_CR47","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1097\/CCM.0b013e3182a16946","volume":"41","author":"ME Wilcox","year":"2013","unstructured":"Wilcox, M. E. et al. Cognitive dysfunction in ICU patients: Risk factors, predictors, and rehabilitation interventions. Crit Care Med. 41(9 Suppl 1), S81-98 (2013).","journal-title":"Crit Care Med."},{"issue":"4","key":"39698_CR48","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1097\/01.CCM.0000059996.30263.94","volume":"31","author":"JC Jackson","year":"2003","unstructured":"Jackson, J. C. et al. Six-month neuropsychological outcome of medical intensive care unit patients. Crit Care Med. 31(4), 1226\u20131234 (2003).","journal-title":"Crit Care Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39698-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39698-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39698-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T04:09:40Z","timestamp":1700453380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-39698-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["39698"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-39698-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1959033\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"13 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). All the other authors declare they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13144"}}